喹硫平治疗老年痴呆患者精神行为症状的临床观察

目的 观察喹硫平与奋乃静对老年痴呆患者的疗效和安全性.方法 将52例老年痴呆患者随机分成两组:研究组给予喹硫平治疗,剂量范围为50～400 mg/d(26例);对照组给予奋乃静治疗,剂量范围为6～16 mg/d(26例),观察8周.采用简易智力状态检查(MMSE)、老年临床评定量表(SCAG)、副反应量表(TESS)分...

Quetiapine for the behavioral and psychological symptoms in senile dementia

Objective To explore the efficacy and safety of quetiapine and perphenazine in the treatment of Alzheimer's disease. Metbods 52 patients were randomly assigned to receive quetiapine of SO - 400mg daily ( 26 patients, study group), or perphenazine of 6-16mg daily ( 26 patients, control group )for 8 weeks. The efficacy and safety of the two therapies was compared between the two groups by using the Mini-mental State Examination ( MMSE ), Sandoz Clincal Assessment Geriatric ( SCAG ), and Treatment Emergent Symptom Scale (TESS ) 8 weeks after treatment. Results At the completion of treatment, the scores on MMSE were significantly higher ( P< 0.01 ), and those on SCAG were significantly lower in both groups ( P< 0.01 or P< 0.05 ), as compared with the baseline scores. The rate of adverse reactions was significantly lower in the study group than in the control group ( 30.8% vs. 46.2%, P< 0.05 ) Conclusions Quetiapine has a better efficacy in the treatment of Alzheimer's disease and has fewer adverse reactions. It is suitable for clinical use.